Phase 3 STRIVE Study Of VX-770 Showed Durable Improvements In Lung Function And Other Measures Of Disease Among People With A Specific Type Of CF
Originally posted in Cystic Fibrosis News From Medical News Today
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the final results from its pivotal Phase 3 STRIVE study that evaluated VX-770, a medicine in development that targets the defective protein that causes cystic fibrosis (CF). STRIVE was designed to evaluate VX-770 among 161 people 12 years or older with a mutation known as G551D in the CF gene…
No Comments »
RSS feed for comments on this post. TrackBack URL
by Raelene
